Will Tilton

Will Tilton joined Sarepta in 2019 as vice president, corporate strategy and program management, responsible for leading and developing the Company’s long-rage strategic planning process across its three core technologies – RNA, gene therapy and gene editing. At the end of 2020, he was named sr. vice president, chief of staff to the president and CEO, Doug Ingram. As chief of staff and a member of Sarepta’s executive team, Will serves as a strategic advisor to the CEO and other senior leaders, collaborating across the organization to ensure the Company’s strategic business initiatives are successfully executed and are aligned to Sarepta’s vision and mission.

Will’s 30-year career in pharmaceuticals began as a research scientist focusing on drug formulation at Perrigo. From there, and after earning his MBA, he advanced into leadership positions in technical operations, supply chain and portfolio management. He joined Shire in 2002 as the company was poised for tremendous growth - expanding from just a few hundred employees to over 23,000 when he left in 2019. During his tenure at Shire, Will moved into increasingly senior roles. As group vice president, he was responsible for all business development due diligence, including in-licensing and material M&A across a full range of early/pre-clinical opportunities through commercial assets. He led Shire’s Integration Management Office (IMO) encompassing more than $40B in M&A opportunities. The IMO, including Baxalta and Dyax, integrated 3 major franchises totaling $6B in annual revenue, 20+ pipeline assets, 11 manufacturing sites, and 16,000 employees across 100+ countries. He also led the Shire side of the Takeda/Shire ($60B) merger to provide a smooth transition, balancing the interests of Shire shareholders, patients, and employees.

Will received his MBA from The Wharton School, University of Pennsylvania, Philadelphia, PA, majoring in Finance, and a B.S. in Chemical Engineering from Michigan State University, East Lansing, MI. He also serves on the Advisory Board of Directors for Company One, a professional theater organization in Boston, MA.